港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

生物醫藥B類股

430.463

+8.7162.07%

漲家數：27

跌家數：4

平家數：3

市盈率：- -

高：431.911

開：421.747

低：421.747

收：421.747

資料載入中...

總覽新聞資訊

兆科眼科-B盤中異動急速拉昇5.26%

耐立克®治療費城染色體陽性（Ph+）急性淋巴細胞白血病（ALL）獲突破性療法認定

基石藥業-B盤中異動大幅拉昇5.04%報3.750港元

永泰生物-B盤中異動早盤股價大漲5.62%

邁博藥業-B盤中異動早盤急速上漲6.06%

華領醫藥-B盤中異動早盤快速上漲5.33%

心通醫療-B盤中異動股價大漲12.87%

藥明巨諾-B盤中異動股價大漲5.47%報2.120港元

李氏大藥廠盤中異動股價大漲5.26%

沛嘉醫療-B盤中異動股價大漲6.00%

德琪醫藥-B盤中異動急速拉昇5.67%

亞盛醫藥(06855.HK)耐立克獲內地納入“突破性治療品種”名單

阿斯达克财经

和鉑醫藥(02142.HK)收到Windward Bio授權協議首付款

阿斯达克财经

【中信建投：AI製藥潛力釋放，有望重塑醫藥未來圖景】中信建投研報表示，AI製藥領域正經歷着快速的迭代和變革，算法的更新迭代和算力的支持為AI在製藥領域的應用打下了良好的基礎。目前AI算法在臨牀前藥物發現階段已經有着深入且深刻的應用，海外頭部臨牀CRO公司在臨牀試驗中已經佈局AI多年，完全由AI研發的新藥有望在1-2年內成功上市。AI有望重塑藥物發現的模式，並且為製藥行業帶來潛移默化且持續地降本增效，驅動AI製藥管線和市場的快速增長，看好AI製藥行業長期的發展潛力及前景。

中信建投：AI製藥潛力釋放，有望重塑醫藥未來圖景

【基石藥業-B(02616.HK)在澳大利亞遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤的臨牀試驗申請】基石藥業-B(02616.HK)發佈公告，公司已在澳大利亞成功遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤(DLBCL)的Ib期臨牀試驗申請。此外 CS5001單藥及聯合PD-L1單抗治療晚期實體瘤的全球多中心臨牀試驗也在同步開展。

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574"},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":430.4633,"timestamp":1741248510375,"preClose":421.74713,"halted":0,"volume":196751826,"delay":0,"changeRate":0.020667,"change":8.716156,"pbRate":3.352817,"amount":2078205803,"amplitude":0.024099,"prevYearClose":331.1933,"fiveDayClose":431.446,"twentyDayClose":333.662,"turnoverRate":0.00762,"marketCap":241153069920,"floatMarketCap":226975358368,"peRate":-16.712341},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":431.91098,"amplitude":0.024099,"preClose":421.74713,"low":421.74713,"pbRate":"3.352817","latestPrice":430.4633,"volume":196751826,"delay":0,"open":421.74713,"prevYearClose":331.1933,"prevWeekClose":411.011,"prevMonthClose":411.011,"prevQuarterClose":331.193,"fiveDayClose":431.446,"twentyDayClose":333.662,"sixtyDayClose":346.493,"secType":"PLATE","market":"HK","turnoverRate":0.00762,"peRate":-16.712341,"marketCap":241153069920,"floatMarketCap":226975358368,"timestamp":1741248510375,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":27,"down":4,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:16,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2517577908","title":"兆科眼科-B盤中異動 急速拉昇5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517577908","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517577908?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:43","pubTimestamp":1741225439,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时43分，兆科眼科-B股票出现异动，股价快速上涨5.26%。截至发稿，该股报2.200港元/股，成交量135.65万股，换手率0.25%，振幅4.78%。兆科眼科-B股票所在的药品行业中，整体涨幅为0.19%。其相关个股中，德琪医药-B、兆科眼科-B、精优药业涨幅较大，振幅较大的相关个股有顺腾国际控股、德琪医药-B、兴科蓉医药，振幅分别为11.54%、8.16%、5.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094359989de08b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094359989de08b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1587","BK1191","BK1574","06622","BK1583"],"gpt_icon":0},{"id":"2517908543","title":"耐立克®治療費城染色體陽性（Ph+）急性淋巴細胞白血病（ALL）獲突破性療法認定","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908543","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517908543?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:42","pubTimestamp":1741225320,"startTime":"0","endTime":"0","summary":"美国马里兰州罗克维尔市和中国苏州2025年3月6日 /美通社/ -- 致力于在血液肿瘤等领域开发创新药物的领先的生物医药企业——亚盛医药今日宣布，公司原创1类新药奥雷巴替尼获国家药品监督管理局药品审评中心纳入\"突破性治疗品种\"名单，用于联合化疗一线治疗新诊断费城染色体阳性（Ph+）急性淋巴细胞白血病患者。此次耐立克获纳入突破性治疗品种，显示了该药物在Ph+ ALL这一预后恶劣的血液肿瘤治疗领域具重大临床潜力和价值。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4634781_ZH34781_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["06855","BK1574","ALL","BK4107","LU2355687059.USD","BK4585","LU0985320562.USD","BK4588","BK4139","AAPG","LU1571399168.USD","LU1699723380.USD","BK4533","BK1161"],"gpt_icon":0},{"id":"2517972404","title":"基石藥業-B盤中異動 大幅拉昇5.04%報3.750港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517972404","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517972404?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:41","pubTimestamp":1741225285,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时41分，基石药业-B股票出现波动，股价快速上涨5.04%。截至发稿，该股报3.750港元/股，成交量184.35万股，换手率0.14%，振幅4.76%。资金方面，该股资金流入426.485万港元，流出177.93万港元。基石药业-B股票所在的生物技术行业中，整体涨幅为0.93%。其相关个股中，科伦博泰生物-B、创胜集团-B、复宏汉霖涨幅较大，振幅较大的相关个股有华领医药-B、复宏汉霖、百奥赛图-B，振幅分别为7.79%、6.96%、6.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094125a2618866&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094125a2618866&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02616","BK1161","BK1574"],"gpt_icon":0},{"id":"2517373970","title":"永泰生物-B盤中異動 早盤股價大漲5.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517373970","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517373970?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:41","pubTimestamp":1741225265,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时41分，永泰生物-B股票出现异动，股价急速拉升5.62%。永泰生物-B股票所在的生物技术行业中，整体涨幅为0.93%。其相关个股中，创胜集团-B、复宏汉霖、科伦博泰生物-B涨幅较大，振幅较大的相关个股有华领医药-B、复宏汉霖、百奥赛图-B，振幅分别为7.79%、6.96%、6.79%。永泰生物-B公司简介：永泰生物制药有限公司是一家主要从事用于治疗癌症的细胞免疫产品的研发、制造及商业化业务的中国投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094108963b76f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094108963b76f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","BK1161","BK1574"],"gpt_icon":0},{"id":"2517972476","title":"邁博藥業-B盤中異動 早盤急速上漲6.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517972476","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517972476?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:40","pubTimestamp":1741225229,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时40分，迈博药业-B股票出现异动，股价快速上涨6.06%。截至发稿，该股报0.350港元/股，成交量1.6万股，换手率0.00%，振幅0.00%。迈博药业-B股票所在的生物技术行业中，整体涨幅为0.93%。迈博药业-B公司简介：迈博药业有限公司是一家主要从事研究、开发和生产用于癌症和自身免疫疾病的单克隆抗体药物的中国公司。该公司主要在中国境内经营业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094029963b76aa&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306094029963b76aa&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02181","BK1161","BK1574"],"gpt_icon":0},{"id":"2517970360","title":"華領醫藥-B盤中異動 早盤快速上漲5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517970360","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517970360?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:36","pubTimestamp":1741225003,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时36分，华领医药-B股票出现波动，股价快速上涨5.33%。截至发稿，该股报2.570港元/股，成交量180.55万股，换手率0.17%，振幅6.97%。华领医药-B股票所在的生物技术行业中，整体涨幅为0.93%。其相关个股中，创胜集团-B、宜明昂科-B、科伦博泰生物-B涨幅较大，振幅较大的相关个股有华领医药-B、百奥赛图-B、昭衍新药，振幅分别为6.97%、6.79%、5.44%。华领医药-B公司简介：华领医药是一家主要从事药物开发业务的中国公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093643963b7525&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093643963b7525&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1574","02552"],"gpt_icon":0},{"id":"2517972405","title":"心通醫療-B盤中異動 股價大漲12.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517972405","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517972405?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:36","pubTimestamp":1741224979,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时36分，心通医疗-B股票出现异动，股价大幅上涨12.87%。截至发稿，该股报1.140港元/股，成交量407.9万股，换手率0.17%，振幅9.90%。资金方面，该股资金流入222.465万港元，流出130.824万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。其相关个股中，心通医疗-B、沛嘉医疗-B、微创医疗涨幅较大，振幅较大的相关个股有心通医疗-B、GUANZE MEDICAL、沛嘉医疗-B，振幅分别为9.90%、8.82%、6.47%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093619989ddd1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093619989ddd1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1100","BK1574","02160","BK1583"],"gpt_icon":0},{"id":"2517724779","title":"藥明巨諾-B盤中異動 股價大漲5.47%報2.120港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517724779","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517724779?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:32","pubTimestamp":1741224757,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时32分，药明巨诺-B股票出现异动，股价快速拉升5.47%。截至发稿，该股报2.120港元/股，成交量5000股，换手率0.00%，振幅1.00%。资金方面，该股资金流入1.053万港元，流出0港元。药明巨诺-B股票所在的生物技术行业中，整体涨幅为1.38%。其相关个股中，创胜集团-B、药明巨诺-B、宜明昂科-B涨幅较大，振幅较大的相关个股有百奥赛图-B、昭衍新药、康宁杰瑞制药-B，振幅分别为6.79%、5.15%、4.13%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093238963b7348&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093238963b7348&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02126","BK1574","BK1583"],"gpt_icon":0},{"id":"2517397089","title":"李氏大藥廠盤中異動 股價大漲5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517397089","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517397089?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:31","pubTimestamp":1741224717,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时31分，李氏大药厂股票出现波动，股价大幅拉升5.26%。截至发稿，该股报1.400港元/股，成交量1500股，换手率0.00%，振幅5.26%。李氏大药厂股票所在的药品行业中，整体涨幅为0.11%。其相关个股中，德琪医药-B、李氏大药厂、精优药业涨幅较大，振幅较大的相关个股有顺腾国际控股、德琪医药-B、李氏大药厂，振幅分别为11.54%、5.67%、5.26%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093157abea6d9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093157abea6d9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","00950","06622","BK1583","BK1587","BK1574"],"gpt_icon":0},{"id":"2517265972","title":"沛嘉醫療-B盤中異動 股價大漲6.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517265972","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517265972?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:31","pubTimestamp":1741224717,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时31分，沛嘉医疗-B股票出现波动，股价大幅拉升6.00%。截至发稿，该股报4.420港元/股，成交量28.2万股，换手率0.04%，振幅6.47%。沛嘉医疗-B股票所在的医疗设备及用品行业中，整体涨幅为0.12%。其相关个股中，心通医疗-B、沛嘉医疗-B、微创机器人-B涨幅较大，振幅较大的相关个股有心通医疗-B、沛嘉医疗-B、智云健康，振幅分别为9.90%、6.47%、4.90%。神经介入业务部门从事研发神经介入手术医疗器械业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093157abea6d99&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093157abea6d99&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1100","09996"],"gpt_icon":0},{"id":"2517597037","title":"德琪醫藥-B盤中異動 急速拉昇5.67%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517597037","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517597037?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 09:31","pubTimestamp":1741224694,"startTime":"0","endTime":"0","summary":"2025年03月06日早盘09时31分，德琪医药-B股票出现异动，股价大幅上涨5.67%。德琪医药-B股票所在的药品行业中，整体涨幅为0.10%。其相关个股中，德琪医药-B、李氏大药厂、精优药业涨幅较大，振幅较大的相关个股有顺腾国际控股、李氏大药厂、德琪医药-B，振幅分别为11.54%、5.26%、4.26%。德琪医药-B公司简介：德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要在亚太地区开展业务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093134989ddb3f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306093134989ddb3f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06996","BK1574","BK1191","BK1583"],"gpt_icon":0},{"id":"2517971778","title":"亞盛醫藥(06855.HK)耐立克獲內地納入“突破性治療品種”名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2517971778","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517971778?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 08:48","pubTimestamp":1741222080,"startTime":"0","endTime":"0","summary":"亚盛医药(06855.HK) 公布，其原创1类新药奥雷巴替尼(商品名：耐立克)获国家药监局(NMPA)药品审评中心(CDE)纳入“突破性治疗品种”名单，用于联合化疗一线治疗新诊断费城染色体阳性(Ph+)急性淋巴细胞白血病(ALL)患者。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201214152343890_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201214152343890_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422529/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","06855","BK1161"],"gpt_icon":0},{"id":"2517716649","title":"和鉑醫藥(02142.HK)收到Windward Bio授權協議首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2517716649","media":"阿斯达克财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517716649?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 08:29","pubTimestamp":1741220940,"startTime":"0","endTime":"0","summary":"和铂医药(02142.HK) 公布，与科伦博泰(06990.HK) 就HBM9378/SKB378向Windward Bio授出独家授权。公司已根据协议收到相应首付款，包括现金付款及Windward Bio母公司的股权。该首付款的到账将进一步充盈公司的现金储备。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-03-05 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1422523/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","02142","BK1161","BK1583"],"gpt_icon":0},{"id":"2517979350","title":"【中信建投：AI製藥潛力釋放，有望重塑醫藥未來圖景】中信建投研報表示，AI製藥領域正經歷着快速的迭代和變革，算法的更新迭代和算力的支持為AI在製藥領域的應用打下了良好的基礎。目前AI算法在臨牀前藥物發現階段已經有着深入且深刻的應用，海外頭部臨牀CRO公司在臨牀試驗中已經佈局AI多年，完全由AI研發的新藥有望在1-2年內成功上市。AI有望重塑藥物發現的模式，並且為製藥行業帶來潛移默化且持續地降本增效，驅動AI製藥管線和市場的快速增長，看好AI製藥行業長期的發展潛力及前景。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517979350","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517979350?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 08:24","pubTimestamp":1741220695,"startTime":"0","endTime":"0","summary":"中信建投研报表示，AI制药领域正经历着快速的迭代和变革，算法的更新迭代和算力的支持为AI在制药领域的应用打下了良好的基础。目前AI算法在临床前药物发现阶段已经有着深入且深刻的应用，海外头部临床CRO公司在临床试验中已经布局AI多年，完全由AI研发的新药有望在1-2年内成功上市。AI有望重塑药物发现的模式，并且为制药行业带来潜移默化且持续地降本增效，驱动AI制药管线和市场的快速增长，看好AI制药行业长期的发展潜力及前景。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06082448553034.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["03347","01477","09939","BK1583","BK0276","BK1161","BK1515","159938","BK1191","BK1141","BK1574","BK1576","601066"],"gpt_icon":0},{"id":"2517976961","title":"中信建投：AI製藥潛力釋放，有望重塑醫藥未來圖景","url":"https://stock-news.laohu8.com/highlight/detail?id=2517976961","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517976961?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 08:16","pubTimestamp":1741220177,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1574","BK0276","BK1141","159938","03347","BK1583","BK1161","BK1576","601066","09939","BK1191","01477","BK1515"],"gpt_icon":0},{"id":"2517497936","title":"【基石藥業-B(02616.HK)在澳大利亞遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤的臨牀試驗申請】基石藥業-B(02616.HK)發佈公告，公司已在澳大利亞成功遞交CS5001(ROR1 ADC)聯合標準治療用於一線瀰漫大B細胞淋巴瘤(DLBCL)的Ib期臨牀試驗申請。此外 CS5001單藥及聯合PD-L1單抗治療晚期實體瘤的全球多中心臨牀試驗也在同步開展。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517497936","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517497936?lang=zh_tw&edition=fundamental","pubTime":"2025-03-06 08:13","pubTimestamp":1741220034,"startTime":"0","endTime":"0","summary":"基石药业-B(02616.HK)发布公告，公司已在澳大利亚成功递交CS5001(ROR1 ADC)联合标准治疗用于一线弥漫大B细胞淋巴瘤(DLBCL)的Ib期临床试验申请。此外 CS5001单药及联合PD-L1单抗治疗晚期实体瘤的全球多中心临床试验也在同步开展。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/06081348552983.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","ADC","BK1161","03347","BK4080","BK1141","02616","BK1583","BK4023","BK4231","BK1576","LU1169590202.USD","PD","LU1169589451.USD"],"gpt_icon":0}],"pageSize":16,"totalPage":43,"pageCount":5,"totalSize":676}]}}